Editas biotech stock drops by 26% over CRISPR patent dispute

 Gene editing outfit Editas has been one of the most successful tech IPO’s of 2016 so far with shares skyrocketing up 130 percent shortly after the company’s public debut. But the stock has now plummeted nearly 26 percent in after-hours trading over concerns it might not be able to legally use the technology it’s built upon. Some on Twitter believe the drop to be part of… Read More